JORGE E CORTES to DNA Modification Methylases
This is a "connection" page, showing publications JORGE E CORTES has written about DNA Modification Methylases.
Connection Strength
0.101
-
Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia. Blood. 2012 Dec 06; 120(24):4840-5.
Score: 0.025
-
Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience. Cancer. 2007 Mar 15; 109(6):1133-7.
Score: 0.017
-
Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia. Cancer. 2007 Feb 15; 109(4):713-7.
Score: 0.017
-
Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol. 2005 Jun 10; 23(17):3948-56.
Score: 0.015
-
Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. Blood. 2004 Mar 01; 103(5):1635-40.
Score: 0.013
-
Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. Cancer. 2003 Aug 01; 98(3):522-8.
Score: 0.013